Lupin rises on getting tentative approval from USFDA for Dolutegravir Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lupin is currently trading at Rs. 901.65, up by 10.75 points or 1.21% from its previous closing of Rs. 890.90 on the BSE.
The scrip opened at Rs. 894.35 and has touched a high and low of Rs. 902.40 and Rs. 894.35 respectively. So far 2716 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 908.65 on 30-Jun-2023 and a 52 week low of Rs. 602.80 on 04-Aug-2022.
Last one week high and low of the scrip stood at Rs. 908.65 and Rs. 884.90 respectively. The current market cap of the company is Rs. 40543.08 crore.
The promoters holding in the company stood at 47.08%, while Institutions and Non-Institutions held 42.52% and 10.40% respectively.
Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Dolutegravir Tablets for Oral Suspension, 5 mg, to market a generic equivalent of Tivicay PD Tablets for Oral Suspension, 5 mg of ViiV Healthcare Company.
This product will be manufactured at Lupin’s Nagpur facility in India. Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD) had estimated annual sales of $1 million in the U.S. (IQVIA MAT March 2023).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
